Status:
UNKNOWN
Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)
Lead Sponsor:
City Hospitals Sunderland NHS Foundation Trust
Collaborating Sponsors:
Takeda
Conditions:
Cerebrovascular Accident
Acute Stroke
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke.
Detailed Description
Lowering blood pressure reduces the risk of first ever and recurrent stroke. There is extensive evidence that blood pressure should be lowered following acute stroke, even from so called normal levels...
Eligibility Criteria
Inclusion
- Acute ischaemic stroke \<72 hours from symptom onset (CT proven)
- Medically stable with no evidence of acute infection and not receiving antibiotic therapy
- Neurologically stable (no progression on NIHSS)
- Able to swallow unthickened fluids safely
- Mean BP (blood pressure) \>120/70 in unaffected arm
Exclusion
- Previous severe disability (Modified Rankin Score \>2)
- Nursing home residents
- Previous history of congestive heart failure requiring treatment with ACE-Inhibitors or angiotensin receptor blockers
- Renal impairment (creatinine \>200 mcgmol/L)
- Women of child bearing potential
- Minors \<18 years of age
- History of dementia without ability to consent
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2007
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00108706
Start Date
December 1 2004
End Date
September 1 2007
Last Update
September 13 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunderland Royal Hospital
Sunderland, Tyne and Wear, United Kingdom, SR4 7TP